The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis.

about

The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis.

Item

http://www.wikidata.org/entity/Q42377257

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

The best platinum regimens for ...... cancer: network meta-analysis.

@en

The best platinum regimens for ...... cancer: network meta-analysis.

@nl

type

Item

label

The best platinum regimens for ...... cancer: network meta-analysis.

@en

The best platinum regimens for ...... cancer: network meta-analysis.

@nl

prefLabel

The best platinum regimens for ...... cancer: network meta-analysis.

@en

The best platinum regimens for ...... cancer: network meta-analysis.

@nl

P1476

The best platinum regimens for ...... cancer: network meta-analysis.

@en

P2093

Akimichi Nagashima

http://www.w3.org/2001/XMLSchema#string

Atsushi Goto

http://www.w3.org/2001/XMLSchema#string

Kentaro Ito

http://www.w3.org/2001/XMLSchema#string

Kentaro Nakashima

http://www.w3.org/2001/XMLSchema#string

Nobuyuki Horita

http://www.w3.org/2001/XMLSchema#string

Takeharu Yamanaka

http://www.w3.org/2001/XMLSchema#string

Takeshi Kaneko

http://www.w3.org/2001/XMLSchema#string

Yuji Shibata

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

The nuts and bolts of PROSPERO: an international prospective register of systematic reviews

Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.

Emerging safety data for bevacizumab in advanced non-small-cell lung cancer.

Simultaneous comparison of multiple treatments: combining direct and indirect evidence.

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

P2888

s41598-017-13724-2

P304

13185

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1038/S41598-017-13724-2

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29030633

http://www.w3.org/2001/XMLSchema#string

P932

5640659

http://www.w3.org/2001/XMLSchema#string